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Purpose: To evaluate the feasibility of pre-operative radiotherapy (54 Gy) with Helical Tomotherapy (HT) followed
by surgery.
Methods and materials: Ten patients with non-metastatic resectable retroperitoneal liposarcomas were treated by
pre-operative tomotherapy (54 Gy) and surgery. Clinical and biological toxicities were evaluated on the CTCAEV3.0
scale. For nine patients, delivered tomotherapy plans were compared with retrospectively-planned dynamic
intensity-modulated radiotherapy (IMRT) dosimetric studies.
Results: No immediate or late Grade>2 toxicities were observed after radiotherapy. Post-operatively, one patient
died and three patients experienced Grade 3 toxicity (two digestive and one metabolic). These toxicities
disappeared and only two patients presented persistent Grade 1 paresthesia. R0 resection was obtained for four
patients, R1 for four, and R2 resection for two. With a median follow-up of 26 months, no local or metastatic
relapse was observed. Dosimetric comparisons between HT and retrospectively-planned IMRT demonstrate
adequate target volume coverage for both techniques. Gastrointestinal sparing is higher with HT with a D200cc
reduced by 5 Gy. Integral dose (ID) was increased in HT.
Conclusions: High dose pre-operative radiotherapy (54 Gy) for retroperitoneal liposarcoma is feasible and mostly
well tolerated. Cumulative toxicity and tolerance depend mainly on patient’s general status. Image-guided radiation
therapy (IGRT) is essential, irrespective of the IMRT technique used. Furthermore, HT offers the possibility of sparing
selected areas in such complex volumes.
Keywords: Retroperitoneal sarcoma, Liposarcoma, Pre-operative radiotherapy, Helical tomotherapy, Intensity
modulated radiotherapy, SurgeryBackground
Retroperitoneal sarcomas represent 12-15% of soft-tissue
sarcomas and liposarcomas are the most common histo-
logical sub-type. They remain asymptomatic for an
extended period and diagnosis is often made only when
considerable growth becomes evident, involving or com-
pressing the surrounding organs. With 5-year local re-
currence rates varying from 35-85% according to
different publications, local control is the principal aim
for managing these tumours [1,2]. Treatment usually
involves an en bloc surgery to remove the tumour and* Correspondence: g.kantor@bordeaux.unicancer.fr
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reproduction in any medium, provided the orthe adjacent viscera, however R0 resections are only
achieved in 60-85% of cases [3-5]. To improve local con-
trol in retroperitoneal sarcomas, combination treatments
including both surgery and radiotherapy have been
developed (from strategies used for soft tissue sarcoma
of the extremities).
One of the major obstacles for radiotherapy (pre-,
intra- or post-operative) is the proximity of adjacent
organs. Reports from studies delivering 45 to 50 Gy have
not confirmed the efficacy of radiotherapy in the treat-
ment of these tumours, nor defined the best therapeutic
sequence [6,7].
In this study we examined high-dose pre-operative ir-
radiation of retroperitoneal liposarcoma. The principal
objective was to evaluate the feasibility of high-doseLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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analysing immediate and late clinical tolerance after
radiotherapy and after surgery. Secondary objectives
were to evaluate the quality of the surgery, local con-
trol and overall survival (OS) rates. Finally, dosimetric
comparisons were made between the helical plan by
HT used for treatment with retrospectively-planned
conformational sliding window intensity-modulated
radiotherapy (IMRT).
Methods and materials
Ten patients with newly diagnosed retroperitoneal lipo-
sarcoma treated consecutively with pre-operative radio-
therapy (HT) and surgery at our Institution between
August 2007 and September 2008 were included in this
pilot, prospective study. All patients were treated by a
unique team consisting of a radiation oncologist and a
surgeon. No chemotherapy was delivered. Patients were
receiving first-line treatment, did not have any metasta-
ses, and presented with tumours that the surgeon judged
to be resectable. Three patients with multiple focality
comprising of sarcomatosis, or history of complicated
prior laparotomies with extensive adhesions precluding
extended field radiotherapy, were excluded. The anato-
mopathologic characteristics are consistent with the
French National Comprehensive Cancer Care Centre
(FFCLCC) classification [8]. Patient characteristics are
described in Table 1. Institutional review board approval
was obtained for this pilot study.
Treatment
Pre-operative radiotherapy by HT
Computed tomography (CT) images were acquired in
two series, before and after intravenous injection to
identify the vascular axis. Contours of the clinical target
volume (CTV) were defined jointly by the surgeon and
the radiation oncologist. The CTV corresponded to theTable 1 Patients and Tumour characteristics for retroperitone
tomotherapy
Patient Gender Age (yrs) ECOG* ASA** Tumour siz
1 F 39 1 1 20
2 F 62 1 1 26
3 M 69 1 1 11
4 M 48 1 2 29
5 M 73 1 2 19.5
6 F 78 1 2 30
7 F 51 1 1 25
8 F 50 1 1 22
9 M 79 1 2 30
10 F 52 1 1 40
*Eastern Cooperative Oncology group.
**American Society of Anesthesiologists.gross tumoral volume (GTV) represented by a high
density zone on the CT scan related to a dedifferentiated
component. This CTV also encompasses the adjacent
fatty structure assumed to be involved. Contact areas
such as posterior wall, adjacent viscera (especially kid-
ney, large bowel and small bowel) were included, as were
the zones of contact between the lesion and the directly
adjacent organs (zones at high risk of R1 resection).
Limits between normal fat and pathologic fat were occa-
sionally difficult to define. The planning target volume
(PTV) was obtained by a 5mm 3D geometric expansion
from the CTV (except for one patient). This margin was
determined after observation of interfraction tumor mo-
tion of retroperitoneal tumour patients treated by
tomotherapy in the department. This small margin is
justified by the limited mobility of these tumours that
are restricted within a confined space as well as by the
daily position monitoring in tomotherapy. The specific
organs at risk (OAR) and constraints are described
Table 2. Small bowel loops were excluded from the PTV
and a virtual space corresponding to the small bowel
without PTV was created.
Treatment planning was carried out with the
Tomotherapy HiArt dedicated inverse planning system.
For each patient this planning was undertaken using a
pitch of 0.3 and a field width of 2.5cm, except for one
patient where a field of 5cm was necessary to minimise
treatment duration. On average, the modulation factor
was 1.62. The dose, prescribed at the median PTV (as
recommended for the ICRU report n°83 dedicated to
IMRT), was 54 Gy, delivered in 30 fractions of 1.8Gy,
five days weekly. The review of the dose volume histo-
grams and of different dosimetric indices (Table 2) also
enabled a quantitative evaluation of treatment plans
[10].
Before each irradiation session, a MegaVoltage scan
was carried out for each patient with the compact HTal liposarcoma patients treated with pre-operative helical
e (cm) Side Histology Grade
Right Dedifferentiated liposarcoma 3
Left Dedifferentiated liposarcoma 3
Left Well-differentiated liposarcoma 1
Right Dedifferentiated liposarcoma 3
Left Dedifferentiated liposarcoma 3
Left Dedifferentiated liposarcoma 3
Left Well differentiated liposarcoma 1
Right Dedifferentiated liposarcoma 1
Right Dedifferentiated liposarcoma 3
Right and left Well-differentiated liposarcoma 1
Table 2 Dosimetric constraints utilized for tomotherapy planning for pre-operative helical tomotherapy
Index Expected value Definition
Target volume
-Planning Target Volume (PTV) V95 >95% Volume receiving at least 95% of prescribed dose
D95 >95% (51.3 Gy) Dose received by 95% of the volume
D98 >90% (48.6 Gy) Dose received by 98% of the volume
D2 <107% (57.8 Gy) Dose received by 2% of the volume corresponding to the “hot spots”
D_mean 54 Gy Average dose (close as possible to the prescribed dose)
Organs at risk
-Gastrointestinal [9] D200cc <50 Gy Dose received by 200cc of the intestinal volume
D2 <54 Gy Dose received by 2% of the volume corresponding to the “hot spots”
V45 <33% Volume receiving 45 Gy
V20 <50% Volume receiving 20 Gy
-Contralateral kidney D2 <12 Gy Dose received by 2% of the volume corresponding to the “hot spots”
-Spinal canal D2 <45 Gy Dose received by 2% of the volume corresponding to the “hot spots”
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scanner, based firstly on an analysis of the concordance
of bone structures, but also on the contralateral kidney
and the target volumes, was carried out.
Surgery
Each patient was seen twice by the surgeon, once before
any treatment, to determine whether the tumour was re-
sectable, and then after radiotherapy to confirm the indi-
cation for surgery. Surgery was performed on average 4
weeks after radiotherapy (from 3 to 6 weeks after). It
consisted of a midline incision for patients in the supine
position then an en bloc resection of the tumour and
involved adjacent organs. Only involved adjacent viscera
were removed, but systematic compartmental resection
was not the goal. Quality of the resection was defined
according to the UICC R (residual tumour) classification
(R0: in sano, R1: microscopic residue, R2: macroscopic
residue).
Methodological considerations
The principal objective of this study was to evaluate
the feasibility of pre-operative HT treatment at 54 Gy.
Tolerance of the therapeutic sequence was evaluated
weekly during radiotherapy, after completion of the ra-
diation treatment, and after surgery using the NCI’s
CTCAE v3.0 scale. Late tolerance was evaluated alter-
nately by the surgeon and the radiotherapist every
three months for the first year and then every six
months. Patient follow-up consisted in a full clinical
examination and regular blood tests with haematology,
electrolytes, kidney function, hepatic function and
serum amylase. Secondary objectives were to evaluate
surgery quality, recurrence-free (RFS) and overall (OS)
survivals. Tomotherapy plans were also compared withretrospectively-planned dynamic IMRT treatment to
define the optimal radiation technique.
Dosimetric comparison between tomotherapy and dynamic
IMRT
Comparative Dynamic IMRT planning was performed
for all patients using the VARIANW Eclipse-Helios soft-
ware with 5 equally distributed fields of 18MV X-
photons. The dosimetric constraints used were the same
for tomotherapy planning. For one patient, it was not
possible to perform the IMRT dosimetry due to the
mechanical characteristics of the multi-leaf collimator
smaller than the size of the largest tumoral axis. Nine
patients were therefore included for these analyses. The
different indices used for this comparison are displayed
in Table 3 as defined in a previous publication [11]. The
minimum PTV dose was defined as the D98%. The
contralateral kidney was evaluated with the Equivalent
Uniform Dose (EUD). Dosimetric data were compared
using the non parametric Wilcoxon’s test at the p<0.05
significance level.
Results
Feasibility and tolerance of the HT treatment
Tolerance during and after radiotherapy
Radiotherapy was well tolerated. All patients finished
their treatment without interruption and no Grade >2
toxicity was observed. Grade 1 fatigue and asthenia were
described by all patients. The main toxicities observed
were digestive. Seven patients showed Grade 1 toxicity
such as anorexia, nausea, vomiting or diarrhoea. Symp-
toms were managed with anti-emetics (metoclopramide,
setrons). One patient presented with Grade 2 nausea
and anorexia. At the end of the radiation, the average
weight loss was 2.5 kg (range: 0–8 kg). One patient
Table 3 Results of the dosimetric comparison between
tomotherapy and intensity-modulated radiotherapy
(IMRT)
Volume Indices Tomotherapy IMRT
Planning Target Volume
(PTV)
V95 (%) 97 96.3
D95 (Gy) 52.4 51.7
D98(Gy) 50.6 50.9
D2 (Gy) 55.2 54.6




Gastrointestinal D2 (Gy) 50.8 51.8
V45 (%) 7.3 10.3
V20 (%) 45.6 45.3
D200cc (Gy) 41.3 46.5
Contralateral kidney D2 (Gy) 8.3 8.9
EUD§ (Gy) 3.9 3.5
Spinal canal D2 32.5 39.1




* SD=Standard Deviation, †DSC=Dice Similarity Coefficient, ††
HI=Homogeneity Index, § EUD= Equivalent Uniform Dose, II RVR= Remaining
Volume at Risk.
(Results in bold indicate statistical significance at the p<0.05 level).
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the form of Grade 1 erythema and one patient showed
transitory Grade 1 toxicity corresponding to the begin-
ning of renal failure, probably of a functional origin
linked to hypovolemia caused by the diarrhoea, vomit-
ing, and weight loss. No changes were observed in pan-
creatic or liver function tests.
Results and immediate tolerance of surgery
R0 surgery was obtained for four patients, R1 for four
patients and R2 for two patients. Resection of the adja-
cent organs was required due to tumoral size, localisa-
tion and local involvement for the: ipsilateral kidney
(10), adrenal gland (7), hemi-colon (3), adnexa (2), and
spleen (2). Muscle resection concerned mainly the psoas
muscles.
Mean hospital stay was eight days. One patient died
36 days after surgery, from a cerebral haemorrhage due
to thrombopenia in the context of sepsis and a disse-
minated intravascular coagulation syndrome. The pa-
tient was 73-years-old, had a WHO score of 1 and
ASA score of 2, with a tumour in close contact with
the iliac vessels. Two other patients had Grade 3 di-
gestive toxicity with significant weight loss. Five
patients displayed Grade 1 digestive toxicity. Meanweight loss was 2 kg after surgery (but the weight of
the surgical specimen removed must be taken into ac-
count). Two patients experienced pain and Grade 1
neuropathies in a form of dermatomal paresthesia after
resection of nerves in the surgical area. This symptom-
atology was a consequence of tumour involvement of
the psoas muscle that was manipulated during surgery.
Finally, one patient presented with a Grade 3 renal fail-
ure (creatinine clearance = 28ml/min). This patient was
77-years-old and had received surgery that was macro-
scopically complete but had a total unilateral nephrec-
tomy. This renal failure was probably linked to a
multifactor kidney malfunction (age, hypovolemia and
nephrectomy).
Tumour control and late toxicity
No patient was lost to follow-up. With a median follow-
up of 26 months (range: 12–36), no local or systematic
recurrence was observed and all nine surviving patients
were in a good general state. No R2 patients presented
local relapses. In terms of delayed toxicities, only two
patients presented persistent and non invalidating pain
and paresthesia in manipulated and irradiated zones.
The other toxicities described during the immediate
postoperative period were all resolved. At the moment
of the last evaluation, patients had gained an average of
three kilos.
Comparative dosimetric analysis
Table 3 summarises the tomotherapy and IMRT dosi-
metric data for each patient. All dosimetric constraints
were respected for the two techniques. For the PTV, the
V95%, D95%, D2% and D_mean are not significantly dif-
ferent across techniques. The minimum PTV dose was
always superior to 95% of the prescribed dose. Prescrip-
tion homogeneity evaluated through the Homogeneity
Index (HI) is the same for the two techniques. In terms
of conformity, the IMRT seems to offer better results
given the higher Dice Similarity Coefficient (DSC) evalu-
ated on the 95% isodose (0.91 compared to 0.88 in
tomotherapy, p=0.0284).
With a V45Gy of 10.3% in IMRT and 7.3% in
tomotherapy (p=0.05), and a D200cc lower by 5Gy in
tomotherapy (p=0.021), gastrointestinal sparing was bet-
ter in tomotherapy. The maximum dose received by the
spinal canal was reduced in tomotherapy (39.1Gy in
IMRT compared to 32.5Gy in tomotherapy; p=0.038),
even though both of these values are far from toxicity
values (Dmax<45Gy). Finally, there were no significant
differences between the two techniques concerning spar-
ing of the contralateral kidney (evaluated by the D2%
and the EUD) (Figure 1).
In terms of the integral dose (ID) administered to
healthy tissue, the comparative analysis is in favour of
Figure 1 Dosimetric comparison between Tomotherapy and intensity-modulated radiotherapy (IMRT) for a left retroperitoneal
liposarcoma (for the same prescribed dose of 54 Gy, note the greater gastrointestinal preservation with helical tomotherapy and the
equivalent controlateral kidney preservation).
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(D’souza et al. [12] or ICRU N°83). Dynamic IMRT with
equally-distributed fields of 18MV photons enables the
reduction of the ID to healthy tissues by 60 joules on
average (p=0.008) compared to HT (Figure 1).Discussion
The mainstay of treatment of retroperitoneal liposarco-
mas is surgery [13,14]. Due to rarity of these tumours,
data on radiotherapy are limited and many questions re-
main unanswered. In the current series focussing on
retroperitoneal liposarcoma treated by high-dose pre-
operative Helical Tomotherapy, toxicity was low to
moderate and mostly grade<3 on the CTCAEV3.0 scale.
During radiotherapy and after surgery, toxicities (which
were mainly digestive), were managed by symptomatic
treatments. After radiotherapy, no Grade>2 toxicity was
observed nor any delayed digestive toxicity. No occlu-
sion or perforation occurred. Furthermore, R0 surgery
was achieved in 40% of cases, R1 for 40% and R2 in the
remaining 20%. With a median follow-up of 26 months,
no local recurrence occurred.Radiotherapy schedule
No randomised study has yet compared results from
radiotherapy administered at different stages of treat-
ment (pre-, intra- or post-operative) [15]. Further, recur-
rence tends to occur at distance after pre-operative
radiation, whereas it is more likely to be local after post-
operative radiation [16]. Pre-operative radiation appears
to offer several advantages compared to post-operative
radiation. The OAR (intestines, liver), repressed by the
tumour are more easily preserved and toxicities, particu-
larly digestive, are reduced. Bossi et al.’s series evaluating
pre-operative voluntarily partial radiation at 50 Gy
shows good tolerance because less than 10% of patients
presented with Grade 3 digestive toxicity [17]. In con-
trast, post-operative radiation seems to result in greater
digestive toxicity. In a series of 45 patients receiving
post-operative radiation of 40.8 to 59.4 Gy, Gilbeau
reports 42% of Grade 2 digestive toxicity [18].
Dose level
Results concerning local control in our series may indi-
cate the superiority of a high dose (54 Gy), but this
would need to be confirmed in a larger prospective trial.
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are expected shortly. Local control appears dose-
dependent [19]. For 104 patients receiving radiation after
complete surgery, Catton et al. showed that time to local
recurrence was 30 months after low dose radiation
(under 35 Gy) vs. 103 months after radiation at doses
higher than 35 Gy (p=0.06) [1].
The increase in pre-operative or post-operative radi-
ation doses requires the use of new radiation techniques
(intensity modulation) to allow sufficient sparing of
healthy surrounding tissues. Theoretical and clinical
dosimetric studies have already shown that the doses
delivered can be increased with IMRT. In a previous
study [6], the post-operative use of IMRT enabled the
dose to be raised to 54 Gy instead of 45 Gy in 3-
dimensional conformational radiotherapy (3D-CRT)
while improving the protection factor for surrounding
organs by 20%. The dose reductions outside the PTV
enabled this prescribed dose increase of 9 Gy to reach
54 Gy [6]. Similar results were found by Koshy et al. [20]
or in Bossi et al.’s series with increased gastrointestinal
and renal sparing on dosimetric comparisons between
3D-CRT and IMRT for 10 patients (dose of 50.4 Gy).
With the same dosimetric limitations used for 3D-CRT
planning and in IMRT, the average dose to the small in-
testine decreased from 36 Gy in 3D-CRT to 27 Gy in
IMRT. Tumoral coverage (V95) is improved with IMRT,
increasing from 95.3% to 98.6%. Pre-operatively, Bossi
et al. also found greater renal sparing with IMRT (kidney
volume receiving more the 15 Gy reduced from 19.8cc
in RTC3D to 3.2 cc with IMRT) [17].
Similarly, Tzeng et al. report the results of 16 patients
receiving radiation at 57.5 Gy. Local control was 80%
with only 25% of patients experiencing Grade 2 digestive
toxicity probably due to the fact that the high-dose PTV
was smaller than the standard PTV, and intentionally far
from the small bowel [7].
IMRT techniques
Technological improvements in radiotherapy are ever-
increasing and intensity modulated treatment can be
administered by various means (tomotherapy, dynamic
IMRT, arc therapy, etc.) [21].. The comparative dosim-
etry study shows very good tumoral coverage for the two
techniques examined, with all dosimetric evaluation con-
straints defined by the ICRU N°83 respected. In particu-
lar, homogeneity of coverage, evaluated through HI, is
similar across IMRT and tomotherapy. In terms of con-
formity, the DSC (calculated with the 95% isodose) is
better after IMRT. The use of the 95% isodose for this
comparison is, however, questionable given the possibil-
ities of optimisation offered by these modern techniques.
When evaluation isodoses are increased progressively
from 95 to 100% to calculate the DSC, thus increasingthe constraints and conformational quality, the conform-
ity index approaches the ideal value of 1 in tomotherapy,
whereas in IMRT it moves away from 1 up until the iso-
dose of 98% (p=0.051). In terms of OAR-sparing, digest-
ive organs are spared more in tomotherapy (D200cc
lowered by 5 Gy). Given the short duration of follow-up,
it is however impossible to know the clinical conse-
quences of this dosimetric gain.
It is also particularly important to evaluate the “low
doses” delivered during the intensity modulation treat-
ment [22]. Using a biological model, Hall et al. estimate
that the risk of a second cancer at 10 years is potentially
doubled when an IMRT technique is used compared to
a 3D-CRT across all pathology types [23]. Our compari-
son indicates that the integral dose delivered is weaker
(on average 60 Joules) in dynamic IMRT than in
tomotherapy, irrespective of the calculation method used
(D’Souza or Remaining Volume at Risk, RVR). The inte-
gral dose seems to increase with tomotherapy when
similar energy is used. The larger field length (in a longi-
tudinal direction) of the tomotherapy plans relative to
retrospectively-planned IMRT could be one reason for
these higher integral dose values [22].
However, intensity modulation treatments, given the
high gradients, must be accompanied by daily position
monitoring to ensure accurate target positioning. In
tomotherapy this is ensured by daily megavoltage CT
scans and during arc therapy by daily cone beam CT
scans (CBCT)[24]. Overall, the evaluation of the integral
dose delivered to healthy tissues by a treatment must
take into account both the energy emitted by the radi-
ation itself but also that emitted by the repositioning im-
agery [25].
Conclusions
The low toxicities in our series, both during and imme-
diately after radiotherapy and after surgery, show the
technical and clinical feasibility of a pre-operative radi-
ation strategy at a high dose of 54 Gy for patients with
retroperitoneal liposarcoma. Clinical evaluation of the
age and general status of patients is essential to judge
feasibility. This irradiation must be delivered with inten-
sity modulation to allow for sufficient sparing of sur-
rounding at-risk organs. Tomotherapy, including image-
guided radiation therapy (IGRT) systems, appears to be
an attractive option with regard to gastrointestinal pres-
ervation, especially in large and convex volumes. This
technique enables us to treat safely a larger number of
patients who would not otherwise have been able to re-
ceive radiation. With regard to the delayed effects of in-
tegral dose, only long-term and prospective data will
answer this specific question. In terms of the cancer out-
comes in this series, no local or distant recurrence was
observed with a median follow-up of 26 months, but
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